From Diagnosis to Design: How Physician-Scientists Are Building Future-Ready Pharma Organizations

Recently, I attended my 25th medical school reunion in New Haven, Connecticut. Being with my former classmates brought me right back to that time in our lives when we were filled with conviction, idealism and a shared desire to change the world through medicine. What struck me most, 25 years later, was seeing how each of us has honored that original purpose in our own way. Some stayed in clinical care; others pursued research, education, public health, leadership or industry. But all of us found different pathways to make a meaningful impact. It was a powerful reminder that although our careers may have taken very different shapes, the values that brought us to medicine in the first place still connect us.

My journey into medicine began much like that of many physicians, driven by a genuine desire to help others. After completing my clinical training, I originally pursued an academic path because it allowed me to combine my passion for patient care with my interest in scientific inquiry. What I valued most about academic medicine was the ability to work directly with patients while contributing to research that advanced our understanding of disease and, ultimately, patient care.

Yet, as time went on, I found myself growing impatient. I wanted to extend my impact beyond the boundaries of the clinic or academic institution. I became increasingly focused on finding ways to translate scientific discoveries into real-world solutions that could benefit patients on a larger scale, ensuring that the insights gained could reach those in need now, rather than waiting for incremental change. That is what brought me to pharma, and it is what has kept me here.

The pharmaceutical industry is changing faster than at any point in my career: new modalities, artificial intelligence (AI), digital therapeutics, a deeper understanding of disease at the molecular level and a growing recognition that improving health encompasses far more than treating illness. The future of pharma will belong to organizations that can do two things well: develop better drugs and redesign their operations to bring innovative treatments to market faster, with a value proposition grounded in patient needs. I believe the years ahead will be among the most consequential in pharma, and I am energized by the opportunity to help shape a future that is more innovative, more adaptive and more responsive to the patients we care for.

The difference between changing what you develop and changing how you operate

To understand what this redesign demands, it helps to distinguish between two related but often conflated forms of transformation. The first is scientific advancement. New modalities, targets and mechanisms of action — including gene therapies, cell-based treatments such as chimeric antigen receptor T-cell therapy, and digital therapeutics — are expanding what is possible for patients. This progress matters, and the industry is making meaningful strides. But developing and commercializing these innovations requires capabilities that differ significantly from those built around small molecules, and building those capabilities is a major undertaking.

The second is organizational transformation, and in many ways, it is the more challenge. It involves building the infrastructure, culture and leadership capability to move with the agility these new modalities demand. That requires people who can maintain scientific rigor and adaptive thinking simultaneously, and teams that can shift across modalities while carrying forward the knowledge and experience they have built. It also requires strong change management — one that treats people as capable contributors, helps them apply what they already know in new contexts and creates an environment where rethinking what is possible is encouraged.

AI and digital tools change what medical affairs can do

Organizational readiness is particularly crucial for medical affairs, as the future requires rapid and significant upscaling in the integration of AI, advanced analytics and digital tools. These capabilities provide the opportunity for more precise identification of unmet need, more targeted engagement and execution, and a shift from tracking activity to measuring the impact of scientific exchange and medical strategy. The ability to analyze signals from across the health care ecosystem and to understand what patients and clinicians are experiencing can help us formulate not only better questions but also increase the quality and speed with which we address them.

Realizing that potential calls on us to build not only technical capability but also to develop the confidence, curiosity, and adaptability to use it well. Teams need to cultivate comfort with the ambiguity and experimentation that AI-enabled approaches require. They need to be willing to let data surface insights that challenge existing assumptions, and to act on those insights before the picture is completely certain. Building that relationship with uncertainty takes deliberate investment in how people think and how teams are structured to make decisions, alongside investment in the tools themselves.

Patient-centric operating model

Ultimately, realizing the full potential of any therapeutic innovation requires a genuinely patient-centric approach. For me, that means understanding the broader health ecosystem in which patients live and designing solutions around that reality, with therapeutics as one essential part of improving outcomes. A truly patient-centered organization builds that capability over time and makes patients not just the focus of its decisions but active partners in shaping them.

Seen through that lens, patient centricity also means addressing the social and health system factors that shape whether innovation reaches the people it is intended to help. A treatment may demonstrate clear clinical value, but if patients are not diagnosed appropriately, must navigate fragmented care, encounter coverage and administrative requirements, or lack access to the right clinical expertise, its impact may not be fully realized in practice.

A truly patient-centered approach requires us to account for these realities and to work across functions while engaging the broader stakeholder ecosystem — payers, providers, health systems, patient organizations and communities — as partners in finding solutions.

What leadership requires when you are asking people to change

The organizations that navigate transformation most effectively are those that bring their people with them. Many of us come to this industry because we want our work to make a meaningful difference in patients’ lives. That shared sense of purpose is a profound strength. When people understand why change matters, they are far more willing to stretch, adapt and help build what comes next.

Most of us want to do the right thing. When an organization struggles to adapt, it is often not for lack of commitment but because priorities, processes and support systems have not yet caught up with what people are being asked to do. The role of leadership is to remove those barriers, create the conditions for people to succeed and invest in the capabilities that transformation requires. That begins with listening, assessing organizational readiness, building on what people already know and inspiring confidence in what they can become. That is the kind of future-ready pharma organization worth building.

Emmanuelle Clerisme-Beaty, M.D., is senior vice president of medicine and regulatory, U.S., at Boehringer Ingelheim